Maravai LifeSciences (MRVI) Misses Q2 EPS by 5c, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Wall Street rallies after Democrats win Congress; data center stocks slide
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mail
Get Alerts MRVI Hot Sheet
Join SI Premium – FREE
Maravai LifeSciences (NASDAQ: MRVI) reported Q2 EPS of ($0.05), $0.05 worse than the analyst estimate of $0.00. Revenue for the quarter came in at $73.4 million versus the consensus estimate of $71.64 million.
GUIDANCE:
Maravai LifeSciences sees FY2024 revenue of $265-285 million, versus the consensus of $275.4 million. Adjusted EBITDA (non-GAAP) margins are now expected to be in the range of 20% to 22%.
For earnings history and earnings-related data on Maravai LifeSciences (MRVI) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Airbnb (ABNB) call put ratio 1 call to 1.3 puts into quarter results
- Avnet (AVT) Tops Q1 EPS by 97c ; Offers Guidance
- Marriott Vacations Worldwide (VAC) Tops Q3 EPS by 7c; offers guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
